IgA Nephropathy
113
17
22
49
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
14 trials with published results (12%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
8.0%
9 terminated out of 113 trials
84.5%
-2.1% vs benchmark
34%
38 trials in Phase 3/4
29%
14 of 49 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 49 completed trials
Clinical Trials (113)
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
TESTING -ON Post-Trial ObservatioNal Cohort Study
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Study of BHV-1400 in IgA Nephropathy
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
A Phase IIa Study in Primary IgA Nephropathy Patients
Atrasentan in Patients With IgA Nephropathy
A Study of Probiotics in IgA Nephropathy
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
Atrasentan in Patients With Proteinuric Glomerular Diseases
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
Study of ARO-CFB in Adult Healthy Volunteers
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
A Study of Zigakibart in Adults With IgA Nephropathy